Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on April 4, 2023. The company is an emerging growth company incorporated in Delaware with principal executive offices in Alameda, California. The report details a specific financing event occurring on the date of the report.
Key Financial Metrics and Obligations
The filing discloses the following specific financial actions and terms:
- Debt Drawdown: AgeX drew the remaining $1 million of credit available under an Amended and Restated Secured Convertible Promissory Note dated February 9, 2023.
- Lender: Juvenescence Limited.
- Repayment Date: The outstanding principal balance is due and payable on February 14, 2024.
- Equity Issuance: In connection with the loan draw, AgeX issued warrants to purchase 756,429 shares of common stock.
- Warrant Terms: The exercise price is $0.661 per share, based on the closing price on March 30, 2023.
The filing does not provide current revenue, profit, cash flow, or margin data, as this is a current report regarding a specific transaction rather than a periodic financial statement.
Material Changes
The primary material change reported is the increase in the company's debt obligations by $1 million and the corresponding issuance of unregistered equity securities (warrants) to the lender. This action utilizes the remaining capacity of a previously disclosed credit facility.
Outlook, Risks, and Management Commentary
The filing includes standard forward-looking statements, cautioning that actual results may differ materially from anticipated results due to various risk factors detailed in the company's periodic SEC reports. Management disclaims any obligation to update these statements. The report notes that the terms of the Secured Note are summarized in the company's Annual Report on Form 10-K filed on March 31, 2023.
Investor Verification Checklist
- Verify the total outstanding principal balance of the Secured Note after this $1 million draw.
- Review the full text of the Amended and Restated Secured Convertible Promissory Note (referenced in the March 31, 2023, 10-K) for conversion terms and covenants.
- Confirm the dilution impact of the 756,429 warrants issued at the $0.661 exercise price.
- Assess the company's liquidity position relative to the February 14, 2024, repayment deadline.